Australia markets closed

GSK plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
21.200.00 (0.00%)
At close: 11:20AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.20
Open22.12
Bid0.00 x 0
Ask0.00 x 0
Day's range21.20 - 21.20
52-week range16.65 - 22.12
Volume137
Avg. volume1,431
Market cap87.665B
Beta (5Y monthly)0.26
PE ratio (TTM)13.95
EPS (TTM)1.52
Earnings dateN/A
Forward dividend & yield0.81 (3.82%)
Ex-dividend date22 Feb 2024
1y target estN/A
  • Reuters

    UPDATE 1-U.S. FDA approves Akebia's anemia drug

    The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.

  • Simply Wall St.

    With 83% ownership of the shares, GSK plc (LON:GSK) is heavily dominated by institutional owners

    Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...

  • Insider Monkey

    12 Best Biotech Penny Stocks to Invest In

    In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]